Johnson & Johnson and Bayer's Xarelto already heads up the pack of new-age anticoagulants, but the pair isn't quitting while it's ahead. Instead, the drugmakers are looking to expand that market lead with new clinical trials aimed at widening the drug's label.
What's an OTC drugmaker worth in the race to the top of the consumer healthcare space? Potentially more than $5.3 billion, if that drugmaker is Belgium's Omega Pharma.
The European Commission has approved Bayer's Eylea (aflibercept) for the treatment of diabetic macular edema, the most common cause of vision loss among people with diabetes.
The release of Bayer's second-quarter earnings report came with an undeniable level of allure for investors interested in the rise of the animal health industry. Responding to an analyst, CEO Marijn Dekkers acknowledged the German-based company was in talks over the future of its animal health division--sparking curiousity regarding possible future M&A.
Bayer's drug business has been on a roll, thanks to some serious growth in its 5 newest products, including the clot-fighter Xarelto and the PAH med Adempas.
In March, Bayer CEO Marijn Dekkers boldly predicted that the company's 5 new drugs--including the blood thinner Xarelto and the macular degeneration treatment Eylea--would help his company achieve 8% annual sales growth through 2016. Judging from the company's second quarter results, Bayer is well on its way to making good on that goal.
It is fascinating what has happened in the last couple of years in the animal health industry, which runs to $22 billion a year for animal drugs and vaccines and is expected to grow at 5.7% compound annual rate, faster than the market for human medicines.
Nexavar, the blockbuster cancer drug sold by Bayer and Onyx Pharmaceuticals, has failed again in a trial for a new indication.
As the FDA continues its effort to phase out antimicrobials, the numbers aren't looking so good for the contracting market.
Bayer HealthCare has scored approval for the first chewable drug approved by the agency for treating osteoarthritis in dogs, a disease that accounts for pain in about 20% of canines older than one year.